Journal SAM: PET Imaging of Proliferation with Pyrimidines
Release Date: 6/1/2013
Expiration Date: 6/30/2016
Member: $45
Non-Member: $90
Continuing Education Credit Information
ABNM SAM Credit
The
American Board of Nuclear Medicine has reviewed and approved this Journal SAM
activity submitted by the SNMMI. This activity fulfills the requirements of the
ABNM Maintenance of Certification program for self-assessment. 2.0
SAMs have been awarded for this activity.
AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is
accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to provide continuing medical education for physicians.
SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Objectives
On successful
completion of this activity, participants should be able to discuss:
1. The
radiopharmaceuticals used to evaluate cell proliferation.
2. The
normal biodistribution of these radiopharmaceuticals.
3. The
role of these radiopharmaceuticals in the evaluation of malignancies.
The
LLSAP is designed for all nuclear medicine specialists and other physicians,
pharmacists and technologists who practice diagnostic and/or therapeutic
nuclear medicine.
Omid S. Tehrani1 and
Anthony F. Shields2
1, 2 Department
of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit,
Michigan
Disclosure
In
accordance with ACCME Revised Standards for Commercial Support and SNM
Conflict-of-Interest Policy, the authors have indicated no relevant
relationships that could be perceived as a real or apparent conflict of
interest. Disclosure of a relationship is not intended to suggest or to condone
bias but is made to provide participants with information that might be of
potential importance to their evaluation of the activity.
